Review




Structured Review

Affinity Biosciences patched 1 antibody
Patched 1 Antibody, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patched+1+antibody/and+ptch1++1+1000+dilution+++af5202+/pm38573544-96-20-27
Average 90 stars, based on 1 article reviews
patched 1 antibody - by Bioz Stars, 2026-10
90/100 stars

Images

Related Articles

Blocking Assay:

Article Title: EHMT2 Suppresses ARRB1 Transcription and Activates the Hedgehog Signaling to Promote Malignant Phenotype and Stem Cell Property in Oral Squamous Cell Carcinoma.
Article Snippet: Oral squamous cell carcinoma (OSCC) represents the primary subtype of head and neck squamous cell carcinoma (HNSCC), characterized by a high morbidity and mortality rate.. Although previous studies have established specific correlations between euchromatic histone lysine methyltransferase 2 (EHMT2), a histone lysine methyltransferase, and the malignant phenotype of OSCC cells, its biological functions in OSCC remain largely unknown.. This study, grounded in bioinformatics predictions, aims to clarify the influence of EHMT2 on the malignant behavior of OSCC cells and delve into the underlying mechanisms.

Incubation:

Article Title: EHMT2 Suppresses ARRB1 Transcription and Activates the Hedgehog Signaling to Promote Malignant Phenotype and Stem Cell Property in Oral Squamous Cell Carcinoma.
Article Snippet: Oral squamous cell carcinoma (OSCC) represents the primary subtype of head and neck squamous cell carcinoma (HNSCC), characterized by a high morbidity and mortality rate.. Although previous studies have established specific correlations between euchromatic histone lysine methyltransferase 2 (EHMT2), a histone lysine methyltransferase, and the malignant phenotype of OSCC cells, its biological functions in OSCC remain largely unknown.. This study, grounded in bioinformatics predictions, aims to clarify the influence of EHMT2 on the malignant behavior of OSCC cells and delve into the underlying mechanisms.



Similar Products

94
Developmental Studies Hybridoma Bank mouse antibody
Mouse Antibody, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patched+1+antibody/anti-Patched/pmc12913813-407-5-12
Average 94 stars, based on 1 article reviews
mouse antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

93
R&D Systems anti patched1
Anti Patched1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patched+1+antibody/Human%2FMouse+Patched+1%2FPTCH+(First+Extracellular+Loop)+Antibody/pm41199529-62-47-48
Average 93 stars, based on 1 article reviews
anti patched1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
R&D Systems monoclonal rat anti ptch1 antibody
A . Relative <t>PTCH1</t> RNA expression in TNBC (red), Her2 (blue), luminal B (LB, green), and luminal A (LA, orange) in the TCGA cohort is illustrated by box plots (log 2 transformed). Outliers are shown within each population (open circles). Student’s t test was used to compare RNA levels between two groups. The p values are indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05). B . Normalized PTCH1 mRNA expression according to TNBC (IHC) status from all DNA microarray data from bc-GenExMiner v4.5 illustrated by box plots (log 2 transformed) (Jezequel et al 2021). C . Boxplots showing PTCH1 mRNA expression (normalized counts from RNA seq data) in circulating tumor cells (CTC) isolated from metastasis breast cancer patient peripheral blood (Wurth R et al 2025). D . High PTCH1 mRNA expression is associated with a poorer prognosis in breast cancer. Distant Metastasis Free Survival (DMFS) and disease-free survival (DFS) data based on PTCH1 mRNA expression were obtained using the exhaustive prognostic analysis on all status breast cancers on the bc-GenExMiner v4.5 web portal, and illustrated by Kaplan–Meier (KM) curves for all ER and PR breast cancers with positive nodules. The obtained Hazard Ratio (HR) with 95% confidence interval and log-rank p-values are shown.
Monoclonal Rat Anti Ptch1 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patched+1+antibody/Mouse+Patched+1%2FPTCH+Antibody/bio_rxiv__2025__09__03__673759-53-35-40
Average 93 stars, based on 1 article reviews
monoclonal rat anti ptch1 antibody - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

93
Novus Biologicals ptch1
A . Relative <t>PTCH1</t> RNA expression in TNBC (red), Her2 (blue), luminal B (LB, green), and luminal A (LA, orange) in the TCGA cohort is illustrated by box plots (log 2 transformed). Outliers are shown within each population (open circles). Student’s t test was used to compare RNA levels between two groups. The p values are indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05). B . Normalized PTCH1 mRNA expression according to TNBC (IHC) status from all DNA microarray data from bc-GenExMiner v4.5 illustrated by box plots (log 2 transformed) (Jezequel et al 2021). C . Boxplots showing PTCH1 mRNA expression (normalized counts from RNA seq data) in circulating tumor cells (CTC) isolated from metastasis breast cancer patient peripheral blood (Wurth R et al 2025). D . High PTCH1 mRNA expression is associated with a poorer prognosis in breast cancer. Distant Metastasis Free Survival (DMFS) and disease-free survival (DFS) data based on PTCH1 mRNA expression were obtained using the exhaustive prognostic analysis on all status breast cancers on the bc-GenExMiner v4.5 web portal, and illustrated by Kaplan–Meier (KM) curves for all ER and PR breast cancers with positive nodules. The obtained Hazard Ratio (HR) with 95% confidence interval and log-rank p-values are shown.
Ptch1, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patched+1+antibody/Patched+1%2FPTCH+Antibody+-+BSA+Free/pmc12501224-276-32-33
Average 93 stars, based on 1 article reviews
ptch1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

94
Developmental Studies Hybridoma Bank anti ptc antibody
A . Relative <t>PTCH1</t> RNA expression in TNBC (red), Her2 (blue), luminal B (LB, green), and luminal A (LA, orange) in the TCGA cohort is illustrated by box plots (log 2 transformed). Outliers are shown within each population (open circles). Student’s t test was used to compare RNA levels between two groups. The p values are indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05). B . Normalized PTCH1 mRNA expression according to TNBC (IHC) status from all DNA microarray data from bc-GenExMiner v4.5 illustrated by box plots (log 2 transformed) (Jezequel et al 2021). C . Boxplots showing PTCH1 mRNA expression (normalized counts from RNA seq data) in circulating tumor cells (CTC) isolated from metastasis breast cancer patient peripheral blood (Wurth R et al 2025). D . High PTCH1 mRNA expression is associated with a poorer prognosis in breast cancer. Distant Metastasis Free Survival (DMFS) and disease-free survival (DFS) data based on PTCH1 mRNA expression were obtained using the exhaustive prognostic analysis on all status breast cancers on the bc-GenExMiner v4.5 web portal, and illustrated by Kaplan–Meier (KM) curves for all ER and PR breast cancers with positive nodules. The obtained Hazard Ratio (HR) with 95% confidence interval and log-rank p-values are shown.
Anti Ptc Antibody, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patched+1+antibody/anti-Patched/bio_rxiv__2024__07__08__602443-189-6-8
Average 94 stars, based on 1 article reviews
anti ptc antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

90
Affinity Biosciences patched 1 antibody
A . Relative <t>PTCH1</t> RNA expression in TNBC (red), Her2 (blue), luminal B (LB, green), and luminal A (LA, orange) in the TCGA cohort is illustrated by box plots (log 2 transformed). Outliers are shown within each population (open circles). Student’s t test was used to compare RNA levels between two groups. The p values are indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05). B . Normalized PTCH1 mRNA expression according to TNBC (IHC) status from all DNA microarray data from bc-GenExMiner v4.5 illustrated by box plots (log 2 transformed) (Jezequel et al 2021). C . Boxplots showing PTCH1 mRNA expression (normalized counts from RNA seq data) in circulating tumor cells (CTC) isolated from metastasis breast cancer patient peripheral blood (Wurth R et al 2025). D . High PTCH1 mRNA expression is associated with a poorer prognosis in breast cancer. Distant Metastasis Free Survival (DMFS) and disease-free survival (DFS) data based on PTCH1 mRNA expression were obtained using the exhaustive prognostic analysis on all status breast cancers on the bc-GenExMiner v4.5 web portal, and illustrated by Kaplan–Meier (KM) curves for all ER and PR breast cancers with positive nodules. The obtained Hazard Ratio (HR) with 95% confidence interval and log-rank p-values are shown.
Patched 1 Antibody, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patched+1+antibody/and+ptch1++1+1000+dilution+++af5202+/pm38573544-96-20-27
Average 90 stars, based on 1 article reviews
patched 1 antibody - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

93
R&D Systems ptch1
Fig. 5 | SHH pathway is important for malignant transformation in a subset of MPNSTs and a therapeutic target. a Capillary-based immunoassay (WES) con- firming knockout of <t>PTCH1</t> and subsequent increased GLI1 activity in HSC1-λ cells. b Trypan blue counts of parental HSC1-λ and PTCH1-knockout clone. Error bars, s.e.m.; n = 3 biologically independent experiments. c PTCH1-knockout in HSC1-λ cell lines leads to upregulation of SHH pathway (GLI1, GLI2 and SMO). Error bars, s.e.m.; n = 3 biologically independent experiments. d Protein blot confirming knockout of PTCH1 in ipNF06.2A cells. e Trypan blue counts of a parental ipNF06.2A cells and PTCH1-knockout clone. Error bars, s.e.m; n = 3 biologically independent experiments. f PTCH1-knockout in ipNF06.2A leads to upregulation of SHH pathway (GLI1, GLI2 and SMO). Error bars, s.e.m; n = 3 biologically indepen- dent experiments. g Representative images and quantitative cell migration in HSC1-
Ptch1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/patched+1+antibody/Human%2FMouse+Patched+1%2FPTCH+(First+Extracellular+Loop)+Antibody/pm37164978-343-14-15
Average 93 stars, based on 1 article reviews
ptch1 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


A . Relative PTCH1 RNA expression in TNBC (red), Her2 (blue), luminal B (LB, green), and luminal A (LA, orange) in the TCGA cohort is illustrated by box plots (log 2 transformed). Outliers are shown within each population (open circles). Student’s t test was used to compare RNA levels between two groups. The p values are indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05). B . Normalized PTCH1 mRNA expression according to TNBC (IHC) status from all DNA microarray data from bc-GenExMiner v4.5 illustrated by box plots (log 2 transformed) (Jezequel et al 2021). C . Boxplots showing PTCH1 mRNA expression (normalized counts from RNA seq data) in circulating tumor cells (CTC) isolated from metastasis breast cancer patient peripheral blood (Wurth R et al 2025). D . High PTCH1 mRNA expression is associated with a poorer prognosis in breast cancer. Distant Metastasis Free Survival (DMFS) and disease-free survival (DFS) data based on PTCH1 mRNA expression were obtained using the exhaustive prognostic analysis on all status breast cancers on the bc-GenExMiner v4.5 web portal, and illustrated by Kaplan–Meier (KM) curves for all ER and PR breast cancers with positive nodules. The obtained Hazard Ratio (HR) with 95% confidence interval and log-rank p-values are shown.

Journal: bioRxiv

Article Title: Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancer

doi: 10.1101/2025.09.03.673759

Figure Lengend Snippet: A . Relative PTCH1 RNA expression in TNBC (red), Her2 (blue), luminal B (LB, green), and luminal A (LA, orange) in the TCGA cohort is illustrated by box plots (log 2 transformed). Outliers are shown within each population (open circles). Student’s t test was used to compare RNA levels between two groups. The p values are indicated (*P < 0.05; **P < 0.01; ***P < 0.001; ns P > 0.05). B . Normalized PTCH1 mRNA expression according to TNBC (IHC) status from all DNA microarray data from bc-GenExMiner v4.5 illustrated by box plots (log 2 transformed) (Jezequel et al 2021). C . Boxplots showing PTCH1 mRNA expression (normalized counts from RNA seq data) in circulating tumor cells (CTC) isolated from metastasis breast cancer patient peripheral blood (Wurth R et al 2025). D . High PTCH1 mRNA expression is associated with a poorer prognosis in breast cancer. Distant Metastasis Free Survival (DMFS) and disease-free survival (DFS) data based on PTCH1 mRNA expression were obtained using the exhaustive prognostic analysis on all status breast cancers on the bc-GenExMiner v4.5 web portal, and illustrated by Kaplan–Meier (KM) curves for all ER and PR breast cancers with positive nodules. The obtained Hazard Ratio (HR) with 95% confidence interval and log-rank p-values are shown.

Article Snippet: After 1 h at room temperature in blocking buffer (20 mmol/L Tris-HCl pH 7.5, 45 mmol/L NaCl, 0.1 % Tween-20, and 5 % non-fat milk), nitrocellulose membranes were incubated overnight at 4 °C with the monoclonal rat anti-PTCH1 antibody from R&D system biotechne clone 413220 (1/1000), the monoclonal mouse anti-P-gp antibody from abcam (ab3366, 1/1000), the rabbit anti-ABCG2 antibody from GeneTex (GTX50793, 1/500) or the rabbit anti-GAPDH antibody from Elabscience (1/20000).

Techniques: RNA Expression, Transformation Assay, Expressing, Microarray, RNA Sequencing, Isolation

Distant Metastasis Free Survival (DMFS), disease-free survival (DFS) and overall survival (OS) data based on PTCH1 mRNA expression were obtained from the intrinsic molecular subtypes’ prognostic analysis on ER+/HER2-high proliferative breast cancers performed on bc-GenExMiner v4.5 web portal and illustrated by Kaplan–Meier curves. The obtained Hazard Ratio (HR) with 95% confidence interval and log-rank P-values are shown.

Journal: bioRxiv

Article Title: Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancer

doi: 10.1101/2025.09.03.673759

Figure Lengend Snippet: Distant Metastasis Free Survival (DMFS), disease-free survival (DFS) and overall survival (OS) data based on PTCH1 mRNA expression were obtained from the intrinsic molecular subtypes’ prognostic analysis on ER+/HER2-high proliferative breast cancers performed on bc-GenExMiner v4.5 web portal and illustrated by Kaplan–Meier curves. The obtained Hazard Ratio (HR) with 95% confidence interval and log-rank P-values are shown.

Article Snippet: After 1 h at room temperature in blocking buffer (20 mmol/L Tris-HCl pH 7.5, 45 mmol/L NaCl, 0.1 % Tween-20, and 5 % non-fat milk), nitrocellulose membranes were incubated overnight at 4 °C with the monoclonal rat anti-PTCH1 antibody from R&D system biotechne clone 413220 (1/1000), the monoclonal mouse anti-P-gp antibody from abcam (ab3366, 1/1000), the rabbit anti-ABCG2 antibody from GeneTex (GTX50793, 1/500) or the rabbit anti-GAPDH antibody from Elabscience (1/20000).

Techniques: Expressing

A . PTCH1 mRNA expression (log 2 transformed) in various luminal and HER2 breast cancer cell lines (dark green) and in TNBC cell lines (other colors). TNBC cell lines are depicted according to the “Lehmann TNBC subtype” nomenclature : basal-like 1 (yellow), basal-like 2 (pale green), immunomodulatory (brown), luminal androgen receptor (dark pink), mesenchymal (pale pink) and mesenchymal stem-like (pink). B . PTCH1 protein expression in three TNBC cell lines. Western-blot was performed on 50 µg extracts from TNBC cell lines (MDA-MB-231, HCC-38 and MDA-MB-468) with antibodies directed against PTCH1. PTCH1 and GAPDH signals were quantified using ImageJ software. Data presented are the mean ± SEM of at least 3 independent experiments. Significance is calculated using Oneway ANOVA Turkey’s multiple comparisons test and attained at P < 0.05 (*).

Journal: bioRxiv

Article Title: Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancer

doi: 10.1101/2025.09.03.673759

Figure Lengend Snippet: A . PTCH1 mRNA expression (log 2 transformed) in various luminal and HER2 breast cancer cell lines (dark green) and in TNBC cell lines (other colors). TNBC cell lines are depicted according to the “Lehmann TNBC subtype” nomenclature : basal-like 1 (yellow), basal-like 2 (pale green), immunomodulatory (brown), luminal androgen receptor (dark pink), mesenchymal (pale pink) and mesenchymal stem-like (pink). B . PTCH1 protein expression in three TNBC cell lines. Western-blot was performed on 50 µg extracts from TNBC cell lines (MDA-MB-231, HCC-38 and MDA-MB-468) with antibodies directed against PTCH1. PTCH1 and GAPDH signals were quantified using ImageJ software. Data presented are the mean ± SEM of at least 3 independent experiments. Significance is calculated using Oneway ANOVA Turkey’s multiple comparisons test and attained at P < 0.05 (*).

Article Snippet: After 1 h at room temperature in blocking buffer (20 mmol/L Tris-HCl pH 7.5, 45 mmol/L NaCl, 0.1 % Tween-20, and 5 % non-fat milk), nitrocellulose membranes were incubated overnight at 4 °C with the monoclonal rat anti-PTCH1 antibody from R&D system biotechne clone 413220 (1/1000), the monoclonal mouse anti-P-gp antibody from abcam (ab3366, 1/1000), the rabbit anti-ABCG2 antibody from GeneTex (GTX50793, 1/500) or the rabbit anti-GAPDH antibody from Elabscience (1/20000).

Techniques: Expressing, Transformation Assay, Western Blot, Software

Journal: bioRxiv

Article Title: Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancer

doi: 10.1101/2025.09.03.673759

Figure Lengend Snippet:

Article Snippet: After 1 h at room temperature in blocking buffer (20 mmol/L Tris-HCl pH 7.5, 45 mmol/L NaCl, 0.1 % Tween-20, and 5 % non-fat milk), nitrocellulose membranes were incubated overnight at 4 °C with the monoclonal rat anti-PTCH1 antibody from R&D system biotechne clone 413220 (1/1000), the monoclonal mouse anti-P-gp antibody from abcam (ab3366, 1/1000), the rabbit anti-ABCG2 antibody from GeneTex (GTX50793, 1/500) or the rabbit anti-GAPDH antibody from Elabscience (1/20000).

Techniques: Concentration Assay

Fig. 5 | SHH pathway is important for malignant transformation in a subset of MPNSTs and a therapeutic target. a Capillary-based immunoassay (WES) con- firming knockout of PTCH1 and subsequent increased GLI1 activity in HSC1-λ cells. b Trypan blue counts of parental HSC1-λ and PTCH1-knockout clone. Error bars, s.e.m.; n = 3 biologically independent experiments. c PTCH1-knockout in HSC1-λ cell lines leads to upregulation of SHH pathway (GLI1, GLI2 and SMO). Error bars, s.e.m.; n = 3 biologically independent experiments. d Protein blot confirming knockout of PTCH1 in ipNF06.2A cells. e Trypan blue counts of a parental ipNF06.2A cells and PTCH1-knockout clone. Error bars, s.e.m; n = 3 biologically independent experiments. f PTCH1-knockout in ipNF06.2A leads to upregulation of SHH pathway (GLI1, GLI2 and SMO). Error bars, s.e.m; n = 3 biologically indepen- dent experiments. g Representative images and quantitative cell migration in HSC1-

Journal: Nature communications

Article Title: Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.

doi: 10.1038/s41467-023-38432-6

Figure Lengend Snippet: Fig. 5 | SHH pathway is important for malignant transformation in a subset of MPNSTs and a therapeutic target. a Capillary-based immunoassay (WES) con- firming knockout of PTCH1 and subsequent increased GLI1 activity in HSC1-λ cells. b Trypan blue counts of parental HSC1-λ and PTCH1-knockout clone. Error bars, s.e.m.; n = 3 biologically independent experiments. c PTCH1-knockout in HSC1-λ cell lines leads to upregulation of SHH pathway (GLI1, GLI2 and SMO). Error bars, s.e.m.; n = 3 biologically independent experiments. d Protein blot confirming knockout of PTCH1 in ipNF06.2A cells. e Trypan blue counts of a parental ipNF06.2A cells and PTCH1-knockout clone. Error bars, s.e.m; n = 3 biologically independent experiments. f PTCH1-knockout in ipNF06.2A leads to upregulation of SHH pathway (GLI1, GLI2 and SMO). Error bars, s.e.m; n = 3 biologically indepen- dent experiments. g Representative images and quantitative cell migration in HSC1-

Article Snippet: Primary antibodies for B-Actin(1:1000, Cat #8457S, Cell Signaling Technologies), Vinculin(1:30000, Cat #V9264, Sigma Aldrich), PTCH1(1:500,Cat#MAB41051, R&D systems) and APC(1:500, Cat #15270, Abcam) were used.

Techniques: Transformation Assay, Knock-Out, Activity Assay, Migration